Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
New treatments for graft-vs.-host disease, updated dosage for HPV vaccines — and Fred Hutch announces awards for graduate students.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback